Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief Medical Officer

  Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief
  Medical Officer

   - Expertise in the development of numerous commercialized drugs and his
         military background to support Company’s development path -

Business Wire

MORRISVILLE, N.C. -- May 21, 2013

Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT), today announced Col.
(ret.) Charles L. Pamplin III, M.D., was appointed to the position of Chief
Medical Officer effective May 20. In this position, he reports to the Chief
Executive Officer. Dr. Pamplin will be implementing the Company’s strategic
clinical development plan. His responsibilities will include overseeing
Clinical Development of Oxycyte, OBI’s lead product candidate currently in
Phase IIb clinical trials in Israel and Switzerland for traumatic brain
injury, as well as preclinical studies here in the U.S.

Col. (ret) Dr. Charles Pamplin, Chief Medical Officer of Oxygen
Biotherapeutics, Inc. (Photo: Busine ...

Col. (ret) Dr. Charles Pamplin, Chief Medical Officer of Oxygen
Biotherapeutics, Inc. (Photo: Business Wire)

“At this stage, the board felt it is was important to elevate the medical and
product development expertise of the company as we push through our Phase IIb
clinical trials and gather the data necessary to answer the FDA questions
regarding Oxycyte,” said Michael Jebsen, Interim CEO and Chief Financial
Officer. “We believe Dr. Pamplin’s expertise in drug development, the drug
approval process, investor outreach, and strategy, as well as his military
ties will prove highly beneficial to the company immediately, and over the
long term.”

Most recently, Dr. Pamplin has been serving as president of Medicines Oracle,
a medical consultancy to the pharmaceutical industry. Prior to that, he was
Vice President of Clinical Development at King Pharmaceuticals, Inc., which
has been acquired by Pfizer Inc. From May 2000 to March 2007 he was Vice
President, Medical Affairs, at King. At King he contributed to the development
of various adenosine receptor agonists, antagonists, and allosteric modifiers.
He contributed to the development of Estrasorb™, bremelanotide, Remoxy,
Vanquix™, Corvue, and sonodenoson and to the life cycle development of
Altace®, Levoxyl®, and Cytomel®. Prior to joining King Pharmaceuticals, he was
Vice President of Quintiles Americas Internal Medicine Business Unit. He
managed numerous medical specialty programs at Quintiles including women’s
health, urology, and dermatology.

Dr. Pamplin is a licensed and board certified physician and a retired U.S.
Army Colonel (Medical Corps), specializing in Internal Medicine, Clinical
Pharmacology, Business Management, and Medical Informatics. During his 22 year
distinguished military career he contributed to the development of
anti-malarial, antileishmanial, and chemical defense drugs and devices. He
developed prophylactic and therapeutic drug treatments and strategies. In
addition, he has received several military awards and honors, including the
Legion of Merit, the National Defense Service Medal, and the Army Achievement
Medal among others.

After receiving his medical degree from the University of Maryland, he
completed his internship and residency in Internal Medicine at Walter Reed
Medical Center and his post-graduate training in Clinical Pharmacology at
Walter Reed Institute of Research, in Washington, D.C. He is a graduate of the
Command and General Staff College. He received his undergraduate degree from
Wake Forest University.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical products that efficiently
deliver oxygen to tissues in the body. The company has developed a proprietary
perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte^® that is
currently in clinical and preclinical studies for intravenous delivery for
indications such as traumatic brain injury, decompression sickness and stroke.
The company is also developing PFC-based creams and gels for topical delivery
to the skin for dermatologic conditions and potentially wound care. In
addition, the Company has commercialized its Dermacyte^® line of skin care
cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor
Cosmetics of Switzerland.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company’s judgment as of
the date of this release. The forward-looking statements are subject to a
number of risks and uncertainties delays in new product introductions and
customer acceptance of these new products, and other risks and uncertainties
as described in our filings with the Securities and Exchange Commission,
including in the current Form 10-Q filed on March 18, 2013, and our annual
report on Form 10-K filed on July 24, 2012, as well as other filings with the
SEC. The company disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release. This caution is
made under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130521006250/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50637234&lang=en

Contact:

Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-211
SVP, Investor Relations &
Corporate Communications
 
Press spacebar to pause and continue. Press esc to stop.